Plum Bio intends to acquire a biofermentation enterprise in the industry

planning to issue shares to purchase assets and postpone the resumption of trading notice282the board of directors and all directors of the company shall ensure that there are no false records, misleading statements or material omissions in the contents of this announcement, and shall bear individual and joint and several liability for the authenticity, accuracy and completeness of the contents282
Meihua Biotech Group Co., Ltd("Company", "Listed Company") issued the "Suspension Notice of Major Matters" on August 26, 2014 (No2014-043) for planning material mattersIn view of the significant uncertainties in this matter, the Company's shares were suspended from trading on August 26, 2014 in order to ensure fair disclosure of information, safeguard the interests of investors and avoid abnormal volatility in the share priceSubsequently, the Company issued the Notice of Continued Suspension of Major Matters on September 2, 2014, September 10, 2014, September 17, 2014 and September 24, 2014 (Notice Nos2014-045, 2014-046, 2014-047, 2014-048, respectively282
After consultation with the parties to the transaction, a preliminary plan for the transaction was drawn up: the company intends to acquire a biofermentation enterprise in the industry by issuing shares to purchase assets, and to raise supporting funds for the non-public issuance of shares by no more than 10 specific investorsDuring the suspension period, the Company engaged independent financial advisers, legal advisers, auditanding and asset assessment intermediaries to conduct due diligence, audit, evaluation and other work on asset purchases282
Since the suspension, the Company and the parties concerned have actively promoted due diligence, auditing, evaluation and business negotiations on the purchase of assets in this offering of sharesDue to the large number of shareholders involved in the subject matter of the transaction, some shareholders are required to perform the necessary internal approval procedures, and the parties involved in the transaction will need to continue to consult in depth on certain matters of the transaction plan in order to finalize the transaction plan282
In view of this, in order to protect the interests of investors, the Company's shares will continue to be suspended for no more than 30 days from September 30, 2014 upon application282
During the suspension period, the Company and relevant parties will accelerate the process of this transaction, and will promptly fulfill the obligation of information disclosure in accordance with the progress, issue the progress of the relevant matters every five trading days, pending the completion of the relevant work to convene the board of directors to consider the plan, timely announcement and re-licensing282
This announcement is hereby made282
282, September 29, 2014
282 planning to issue shares to purchase assets and postpone the resumption of trading announcement
282 's Board of Directors and all directors to ensure that there are no false records, misleading statements or material omissions in the contents of this announcement, and bear individual and joint liability for the authenticity, accuracy and completeness of its contents 282
　　Meihua Biotech Group Co., Ltd ("Company", "Listed Company") issued the "Suspension Notice of Major Matters" on August 26, 2014 (No 2014-043) for planning material matters In view of the significant uncertainties in this matter, the Company's shares were suspended from trading on August 26, 2014 in order to ensure fair disclosure of information, safeguard the interests of investors and avoid abnormal volatility in the share price Subsequently, the Company issued the Notice of Continued Suspension of Major Matters on September 2, 2014, September 10, 2014, September 17, 2014 and September 24, 2014 (Notice Nos 2014-045, 2014-046, 2014-047, 2014-048, respectively 282
　　After consultation with the parties to the transaction, a preliminary plan for the transaction was drawn up: the company intends to acquire a biofermentation enterprise in the industry by issuing shares to purchase assets, and to raise supporting funds for the non-public issuance of shares by no more than 10 specific investors During the suspension period, the Company engaged independent financial advisers, legal advisers, auditanding and asset assessment intermediaries to conduct due diligence, audit, evaluation and other work on asset purchases 282
　　Since the suspension, the Company and the parties concerned have actively promoted due diligence, auditing, evaluation and business negotiations on the purchase of assets in this offering of shares Due to the large number of shareholders involved in the subject matter of the transaction, some shareholders are required to perform the necessary internal approval procedures, and the parties involved in the transaction will need to continue to consult in depth on certain matters of the transaction plan in order to finalize the transaction plan 282
　　In view of this, in order to protect the interests of investors, the Company's shares will continue to be suspended for no more than 30 days from September 30, 2014 upon application 282
　　During the suspension period, the Company and relevant parties will accelerate the process of this transaction, and will promptly fulfill the obligation of information disclosure in accordance with the progress, issue the progress of the relevant matters every five trading days, pending the completion of the relevant work to convene the board of directors to consider the plan, timely announcement and re-licensing 282
　　This announcement is hereby made 282
　　Meihua Biotech Group Co., Ltd 282 September 29, 2014 282 shared to feed weibo